(0.58%) 5 157.34 points
(0.39%) 38 828 points
(0.57%) 16 248 points
(0.83%) $78.76
(3.55%) $2.22
(1.04%) $2 332.70
(3.57%) $27.64
(0.87%) $973.65
(-0.16%) $0.927
(-0.61%) $10.81
(-0.28%) $0.795
(-0.13%) $91.34
-2.82% INR 345.20
Live Chart Being Loaded With Signals
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables...
Stats | |
---|---|
Объем за сегодня | 3 862.00 |
Средний объем | 10 341.00 |
Рыночная капитализация | 5.55B |
EPS | INR0 ( 2024-02-08 ) |
Дата следующего отчета о доходах | ( INR0 ) 2024-05-27 |
Last Dividend | INR0.500 ( 2019-09-20 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 37.36 |
ATR14 | INR1.193 (0.35%) |
Объем Корреляция
Kilitch Drugs (India) Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Kilitch Drugs (India) Корреляция - Валюта/Сырье
Kilitch Drugs (India) Финансовые показатели
Annual | 2022 |
Выручка: | INR1.40B |
Валовая прибыль: | INR648.40M (46.45 %) |
EPS: | INR6.71 |
FY | 2022 |
Выручка: | INR1.40B |
Валовая прибыль: | INR648.40M (46.45 %) |
EPS: | INR6.71 |
FY | 2022 |
Выручка: | INR1.14B |
Валовая прибыль: | INR488.01M (42.72 %) |
EPS: | INR4.73 |
FY | 2021 |
Выручка: | INR685.23M |
Валовая прибыль: | INR312.16M (45.56 %) |
EPS: | INR2.37 |
Financial Reports:
No articles found.
Kilitch Drugs (India) Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR1.000 | 2010-10-14 |
Last Dividend | INR0.500 | 2019-09-20 |
Next Dividend | INR0 | N/A |
Payout Date | 2019-10-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | INR33.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.31 | -- |
Div. Sustainability Score | 3.63 | |
Div.Growth Potential Score | 3.46 | |
Div. Directional Score | 3.55 | -- |
Year | Amount | Yield |
---|---|---|
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.500 | 0.59% |
2019 | INR0.500 | 0.31% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SAGCEM.NS | Dividend Junior | 2023-06-20 | Annually | 18 | 0.28% | |
LTIM.NS | Dividend Knight | 2023-07-10 | Semi-Annually | 9 | 0.87% | |
GHCL.NS | Dividend Junior | 2023-06-23 | Annually | 22 | 1.62% | |
ARVSMART.NS | No Dividend Player | 2023-07-21 | Sporadic | 6 | 0.13% | |
THOMASCOOK.NS | Dividend Junior | 2023-08-10 | Sporadic | 18 | 0.15% | |
ORIENTPPR.NS | Dividend Junior | 2023-08-01 | Annually | 18 | 1.07% | |
ISGEC.NS | Dividend Junior | 2023-08-14 | Annually | 4 | 0.27% | |
CYBERTECH.NS | Dividend Knight | 2023-09-22 | Annually | 18 | 0.77% | |
SHREECEM.NS | Dividend Junior | 2023-06-01 | Annually | 23 | 0.25% | |
MARKSANS.NS | Dividend Junior | 2023-06-07 | Annually | 11 | 0.40% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0940 | 1.500 | 8.12 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0916 | 1.500 | -0.0933 | -0.140 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 4.20 | 1.000 | 9.56 | 9.56 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 4.15 | 2.00 | 7.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.486 | 1.000 | 5.24 | 5.24 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.158 | 1.000 | 8.85 | 8.85 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.63 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 38.79 | 1.000 | 6.18 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0916 | 2.50 | -0.0600 | -0.140 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.927 | 1.500 | 7.16 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0430 | 1.000 | -1.424 | 0 | [0.1 - 0.5] |
Total Score | 3.46 |
Kilitch Drugs (India)
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа